- 12 January 2021Portfolio NewsBoehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
- 12 January 2021Portfolio NewsArtios Pharma Appoints Abid Ansari as Chief Financial Officer
- 6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
- 16 December 2020Portfolio NewsEnara Bio adds further world‐class cell therapy and immuno‐oncology expertise to Senior Management Team and Scientific Advisory Board
- 9 December 2020Portfolio NewsEnara Bio relocates to The Oxford Science Park's newest facility to expand R&D capabilities in the search for novel cancer immunotherapies
- 3 December 2020Portfolio NewsMerck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
- 23 November 2020Portfolio NewsThe Boston Globe Names Deciphera a Top Place to Work for 2020
- 18 November 2020Portfolio NewsPionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
- 18 November 2020Portfolio NewsSutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
- 17 November 2020Portfolio NewsAVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
- 10 November 2020Portfolio NewsXilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting